Glenmark Generics (Europe) Ltd has an exciting portfolio of 5 approved products, 12 products filed and pending approval; with a further 15 products in development. These are solid and semi-solid products filed as EU CTD dossiers and offered for out-licensing to prospective partners. Most of the portfolio are backed up with vertical integration on APIs. A UK based regulatory and project management team, ably supported by IP & product development infrastructure in India, are the key components of our development, submission and support strategy.